UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

Positive results were announced from its two pivotal phase III trials, B-Well 1 and B-Well 2, evaluating bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B in over 1,800 patients from 29 countries.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

The Alliance for Clinical Trials in Oncology initiated a randomized phase III clinical trial called RECIPROCAL to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.

January 09, 2026

Vol.52 No.1

In Brief

Northwell, START unveil $5.7M early-phase clinical trial center

Northwell Health and START Center for Cancer Research have unveiled a $5.7M, 10,000 square foot early-phase cancer clinical trial center that aims to provide better access to treatments for cancer patients in New York and Long Island.

December 19, 2025

Vol.51 No.46

In Brief

Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

Khalil Choucair has joined the thoracic oncology and phase I clinical trials multidisciplinary teams as a medical oncologist at Karamos Cancer Institute.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

Researchers presented updated data at ESMO IO from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab-dlwr (Zynyz) in combination with platinum-based chemotherapy (carboplatin and paclitaxel) in adult patients with squamous cell carcinoma of the anal canal.

December 19, 2025

Vol.51 No.46

UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials

YOU MAY BE INTERESTED IN

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

Northwell, START unveil $5.7M early-phase clinical trial center

Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

Renew today!

Subscriber content

Never miss an issue!

Login